Women undergoing breast augmentation surgery with implants are at greater risk of developing a rare form of haematological cancer, according to a Dutch study. Researchers at the University’s Medical Center in Amsterdam argue that women with chest implants are at risk of developing anaplastic large cell lymphoma.
It is a rare form of haematological cancer that is considered to be an aggressive form of non-Hodgkin’s lymphoma. In recent years, the number of women diagnosed with anaplastic large cell lymphoma has increased, causing concern that implants cause this neoplasm.
Dutch experts studied data for non-Hodgkin’s lymphoma patients registered in the Dutch Cancer Archive 1990-2016. Among the 43 women with anaplastic large-cell lymphoma in the breast, 32 had breast implants, compared to just one patient out of 146 who had other forms of mammary lymphoma.
In fact, women with macromolecular implants appear to be at greater risk. Among the 28 cases of anaplastic large cell lymphoma known and type of implant, 23 had a macromolecular insert. In contrast, small molecule inserts accounted for only 18% of the study’s reflex large cell lymphoma.
Overall, the results show that women with mammary inserts are 421 times more likely to develop refractory grandchild lymphoma in the chest. But the absolute danger is low, with just one woman per 6,920 with implants being at risk until the age of 75.
“It is important for women to be aware of the risk of regenerative large cell lymphoma when they think of increasing their breast size. Also those who already have inserts should be particularly observant for signs and symptoms and seek immediate medical advice if a breast or nodule is swollen, “said Dr. Daphne de Jong, author of the study.
Researchers speculate that the risk may be due to an immune response or an inflammatory reaction to bacteria on the surface of the inserts, according to Dr de Jong.